Loading...
Gossamer Bio Q4 2024 Earnings Report
Gossamer Bio reported its financial results for the fourth quarter and full year ended December 31, 2024, highlighting progress in its clinical trials and financial position.
Key Takeaways
Gossamer Bio announced a net loss of $33.0 million for Q4 2024, an improvement from the $48.1 million net loss in Q4 2023. The company's total revenue for the quarter was $9.379 million, and it ended the year with $294.5 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the first half of 2027.
PROSERA Phase 3 in PAH is on track for topline data readout in Q4 2025.
Registrational Phase 3 in PH-ILD is expected to commence in H2 2025.
Seralutinib received Orphan Drug Designation for PAH in Japan.
Cash, cash equivalents, and marketable securities totaled $295 million at year-end 2024, sufficient to fund operations into H1 2027.
Gossamer Bio
Gossamer Bio
Gossamer Bio Revenue by Segment
Revenue by Segment
Sale of Licenses Revenue
CapyFin.comContracts with Collaborators Revenue
CapyFin.com Forward Guidance
Gossamer Bio anticipates significant progress in its clinical programs, with key data readouts and trial initiations expected in 2025. The company's current financial resources are projected to support operations into the first half of 2027.
Positive Outlook
- PROSERA Phase 3 in PAH on track for topline data readout in Q4 2025.
- Registrational Phase 3 in PH-ILD expected to commence in H2 2025.
- Seralutinib received Orphan Drug Designation for PAH in Japan, potentially forming the basis for a marketing application.
- Current cash, cash equivalents, and marketable securities are sufficient to fund operating and capital expenditures into H1 2027.
- Continued focus on execution of the PROSERA Study to ensure timely topline results.
Challenges Ahead
- Potential delays in the commencement, enrollment, and completion of clinical trials.
- Disruption to operations from unexpected events, including clinical trial delays.
- Dependence on third parties for product manufacturing, research, and clinical testing.
- Preclinical and early clinical trial results are not necessarily predictive of future results.
- Unexpected adverse side effects or inadequate efficacy of seralutinib that may limit its development or regulatory approval.